Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

Abstract

These results suggest that the combination of docetaxel and cisplatin has moderate toxicity and is an effective regimen for the treatment of advanced gastric cancer, both with regard to response rate and survival.

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

“…Therefore, results must be interpreted with caution, and warrant confirmation in a randomised trial setting. Still, the observed antitumour potential, which is in agreement with the previously mentioned phase II studies of Roth et al (2000) (RR 56%, median survival 9 months), and Ridwelski et al (2001) (RR 37%, median survival 10.4 months), suggests that taxane/cisplatin-based combination chemotherapy might be as active as second-or even third-generation regimens including ECF or the more intense and toxic PELF (Cascinu et al, 1997;Webb et al, 1997). Potential advantages of the described biweekly and other taxane+cisplatin combination regimens are related to the non-requirement of a central venous access and external infusional devices with their associated risks and costs (Lemmers et al, 1996;Kock et al, 1998).…”

“…The continuing lack of substantial progress in the treatment of advanced gastric cancer, particularly in patients with poor performance status or compromised organ function, who are unlikely to tolerate potentially active but toxic regimens, has prompted investigators to evaluate new agents and/or drug combinations including docetaxel, paclitaxel, and irinotecan (Bokemeyer et al, 1997;Boku et al, 1999;Murad et al, 1999;Kollmannsberger et al, 2000;Roth et al, 2000;Ridwelski et al, 2001). …”

“…The rationale for their combined use were: (1) the documented activity of both drugs in gastric cancer when used as single agent (Wils, 1996); (2) the apparent synergistic efficacy and safety of this combination in patients with ovarian-, head and neck cancer, and NSCLC (Ilson et al, 1998;Gatzemeier et al, 2000;Khuri et al, 2000;Pfisterer, 2000); (3) as well as the encouraging results of two recently published reports of a combination of cisplatin and the semisynthetic taxoid docetaxel (Roth et al, 2000;Ridwelski et al, 2001).…”

“…Furthermore, two recently published phase II studies, investigating the combination of cisplatin with docetaxel, a semisynthetic taxoid, suggested a high antitumour activity with an overall response rate of 37 and 56%, respectively (Roth et al, 2000;Ridwelski et al, 2001).…”

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma

“…Docetaxel, which inhibits microtubule depolymerization, has been widely used in the treatment of MGC, with several phase II trials showing that this drug, as a single agent, induces response rates of 16 -24% (Sulkes et al, 1994;Bang et al, 2002). Moreover, when combined with cisplatin, docetaxel has produced response rates of 33 -56% (Roth et al, 2000;Kettner et al, 2001;Ridwelski et al, 2001;Ajani et al, 2005).…”